Table 2. Distribution of miRNA genotypic and allelic frequencies in cervical cancer cases and controls.
| Control (n=150) | Cases (n=150) | P-value | OR (95% CI) | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| miR-146a (rs2910164) | ||||
| Genotype frequency | ||||
| GG | 73 (48.7) | 80 (53.3) | 1.00 (Reference) | |
| GC | 49 (32.7) | 49 (32.7) | 0.823 | 0.91 (0.54–1.52) |
| CC | 28 (18.6) | 21 (14.0) | 0.325 | 0.68 (0.35–1.31) |
| GC+CC | 77 (51.3) | 70 (46.7) | 0.488 | 0.83 (0.53–1.31) |
| Allelic frequency | ||||
| G | 195 (65) | 209 (69.7) | 1.00 (Reference) | |
| C | 105 (35) | 91 (30.3) | 0.258 | 0.81 (0.57–1.14) |
| miR-196 (rs11614913) | ||||
| Genotype frequency | ||||
| CC | 42 (28) | 75 (50) | 1.00 (Reference) | |
| CT | 51 (34) | 58 (38.7) | 0.127 | 0.64 (0.37–1.08) |
| TT | 57 (38) | 17 (11.3) | <0.0001* | 0.17 (0.08–0.32) |
| CT+TT | 108 (72) | 75 (50) | 0.0002* | 0.39 (0.24–0.63) |
| Allelic frequency | ||||
| C | 135 (45) | 208 (69.3) | 1.00 (Reference) | |
| T | 165 (55) | 91 (30.7) | <0.0001* | 0.36 (0.26–0.50) |
| miR-499 (rs3746444) | ||||
| Genotype frequency | ||||
| CC | 80 (53.3) | 78 (52.0) | 1.00 (Reference) | |
| CT | 49 (32.7) | 47 (31.3) | 0.949 | 0.98 (0.59–1.63) |
| TT | 21 (14.0) | 25 (16.7) | 0.617 | 1.22 (0.63–2.36) |
| CT+TT | 70 (46.7) | 72 (48.0) | 0.909 | 1.06 (0.67–1.66) |
| Allelic frequency | ||||
| C | 209 (69.7) | 203 (67.7) | 1.00 (Reference) | |
| T | 91 (30.3) | 97 (32.3) | 0.659 | 1.09 (0.77–1.55) |
P-value, probability from chi-square test comparing the genotypic/allelic distribution in cervical cancer cases and controls. Significant P-values are shown in bold.